$PYPD
PolyPid Ltd Stock $pypd

$pypd Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000121390023025399 Filed on March 31, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.957M	$10.90M	$4.037M
YoY Change	-51.52%	-13.44%	40.17%
% of Gross Profit
Research & Development	$4.655M	$27.99M	$9.617M
YoY Change	-51.6%	-8.39%	91.96%
% of Gross Profit
Depreciation & Amortization		$1.721M
YoY Change		53.94%
% of Gross Profit
Operating Expenses	$6.612M	$27.99M	$13.65M
YoY Change	-51.57%	-35.13%	73.05%
Operating Profit		-$38.89M
YoY Change		-9.87%
Interest Expense	$100.0K	$800.0K	$152.0K
YoY Change	-34.21%	56.25%	-55.29%
% of Operating Profit
Other Income/Expense, Net		-$540.0K
YoY Change		-1787.5%
Pretax Income	-$6.512M	$39.56M	-$13.50M
YoY Change	-51.77%	-192.85%	78.83%
Income Tax	$55.00K	$129.0K
% Of Pretax Income		0.33%
Net Earnings	-$6.567M	-$39.56M	-$13.50M
YoY Change	-51.36%	-7.15%	78.83%
Net Earnings / Revenue
Basic Earnings Per Share		$2.04
Diluted Earnings Per Share	-$0.33	$2.04	-$719.8K
COMMON SHARES
Basic Shares Outstanding	19.85M shares	19.43M shares
Diluted Shares Outstanding		19.43M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.59M	$12.59M	$32.20M
YoY Change	-60.89%	-60.89%	-27.6%
Cash & Equivalents	$8.552M	$8.552M	$9.819M
Short-Term Investments	$4.042M	$4.042M	$22.38M
Other Short-Term Assets	$1.600M	$1.361M	$2.608M
YoY Change	-38.65%	-32.36%	-4.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.19M	$14.19M	$34.81M
YoY Change	-59.23%	-59.23%	-26.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.247M	$11.68M	$8.761M
YoY Change	5.55%	33.3%	48.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$99.00K	$99.00K	$663.0K
YoY Change	-85.07%	-85.07%	-97.09%
Total Long-Term Assets	$11.78M	$11.78M	$9.424M
YoY Change	24.97%	24.97%	-67.11%
TOTAL ASSETS
Total Short-Term Assets	$14.19M	$14.19M	$34.81M
Total Long-Term Assets	$11.78M	$11.78M	$9.424M
Total Assets	$25.97M	$25.97M	$44.24M
YoY Change	-41.29%	-41.29%	-41.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.141M	$1.141M	$4.136M
YoY Change	-72.41%	-72.41%	326.39%
Accrued Expenses	$1.246M	$3.372M	$3.940M
YoY Change	-68.38%	-8.02%	107.37%
Deferred Revenue
YoY Change
Short-Term Debt	$4.024M	$4.024M	$0.00
YoY Change
Long-Term Debt Due	$4.024M
YoY Change
Total Short-Term Liabilities	$8.553M	$8.553M	$8.076M
YoY Change	5.91%	5.91%	180.42%
LONG-TERM LIABILITIES
Long-Term Debt	$7.574M	$7.574M	$0.00
YoY Change
Other Long-Term Liabilities	$16.00K	$4.015M	$199.0K
YoY Change	-91.96%	1917.59%	4.74%
Total Long-Term Liabilities	$16.00K	$11.59M	$199.0K
YoY Change	-91.96%	5723.62%	4.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.553M	$8.553M	$8.076M
Total Long-Term Liabilities	$16.00K	$11.59M	$199.0K
Total Liabilities	$8.569M	$20.14M	$8.275M
YoY Change	3.55%	143.41%	169.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$214.4M		-$174.9M
YoY Change	22.62%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.829M	$5.829M	$35.96M
YoY Change
Total Liabilities & Shareholders Equity	$25.97M	$25.97M	$44.24M
YoY Change	-41.29%	-41.29%	-41.68%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$6.567M	-$39.56M	-$13.50M
YoY Change	-51.36%	-7.15%	78.83%
Depreciation, Depletion And Amortization		$1.721M
YoY Change		53.94%
Cash From Operating Activities		-$34.32M
YoY Change		5.96%
INVESTING ACTIVITIES
Capital Expenditures		$1.767M
YoY Change		-166.6%
Acquisitions
YoY Change
Other Investing Activities		$18.34M
YoY Change		-53.63%
Cash From Investing Activities		$16.58M
YoY Change		-55.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$4.423M
YoY Change		327.76%
Debt Paid & Issued, Net		$402.0K
YoY Change
Cash From Financing Activities		$16.43M
YoY Change		1488.78%
NET CHANGE
Cash From Operating Activities		-$34.32M
Cash From Investing Activities		$16.58M
Cash From Financing Activities		$16.43M
Net Change In Cash		-$1.314M
YoY Change		-123.68%
FREE CASH FLOW
Cash From Operating Activities		-$34.32M
Capital Expenditures		$1.767M
Free Cash Flow		-$36.08M
YoY Change		21.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38428
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	18 Hasivim Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Petach Tikva
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	495376
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value
CY2022	dei	Trading Symbol TradingSymbol	PYPD
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19851833	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1281
CY2022	dei	Auditor Name AuditorName	KOST FORER GABBAY & KASIERER
CY2022	dei	Auditor Location AuditorLocation	Haifa, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8552000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9819000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	511000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	397000	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	4042000	usd
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	22384000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1089000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2211000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14194000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	34811000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9247000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8761000	usd
CY2022Q4	pypd	Longterm Deposits LongtermDeposits	2431000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	99000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	663000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	11777000	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	9424000	usd
CY2022Q4	us-gaap	Assets Assets	25971000	usd
CY2021Q4	us-gaap	Assets Assets	44235000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4024000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2429000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3940000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1141000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4136000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	959000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8553000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8076000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	7574000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2548000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1173000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	294000	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	199000	usd
CY2022Q4	pypd	Total Longterm Liabilities TotalLongtermLiabilities	11589000	usd
CY2021Q4	pypd	Total Longterm Liabilities TotalLongtermLiabilities	199000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	47800000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	47800000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19851833	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19851833	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18756570	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18756570	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220273000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	210847000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-214444000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-174887000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5829000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35960000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25971000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44235000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27990000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30553000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16954000	usd
CY2022	pypd	Marketing And Business Development Expenses MarketingAndBusinessDevelopmentExpenses	2888000	usd
CY2021	pypd	Marketing And Business Development Expenses MarketingAndBusinessDevelopmentExpenses	2983000	usd
CY2020	pypd	Marketing And Business Development Expenses MarketingAndBusinessDevelopmentExpenses	1614000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8010000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9609000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7704000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-38888000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-43145000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-26272000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-540000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	544000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10597000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-39428000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-42601000	usd
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-36869000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	129000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-39557000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-42601000	usd
CY2020	us-gaap	Profit Loss ProfitLoss	-36869000	usd
CY2020	pypd	Deemed Dividends DeemedDividends	-2114000	usd
CY2022	pypd	Net Loss Attributable To Ordinary Sharesin Dollars Per Share NetLossAttributableToOrdinarySharesinDollarsPerShare	-39557000	usd
CY2021	pypd	Net Loss Attributable To Ordinary Sharesin Dollars Per Share NetLossAttributableToOrdinarySharesinDollarsPerShare	-42601000	usd
CY2020	pypd	Net Loss Attributable To Ordinary Sharesin Dollars Per Share NetLossAttributableToOrdinarySharesinDollarsPerShare	-38983000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.28
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.48
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19426692	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18721528	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9582405	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-87632000	usd
CY2020	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4577000	usd
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	62757000	usd
CY2020	pypd	Conversion Of Convertible Preferred Shares To Ordinary Shares ConversionOfConvertiblePreferredSharesToOrdinaryShares	106313000	usd
CY2020	pypd	Reclassification Of Warrants Into Equity ReclassificationOfWarrantsIntoEquity	23614000	usd
CY2020	pypd	Exercise Of Warrants ExerciseOfWarrants	13000	usd
CY2020	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36869000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	72777000	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4750000	usd
CY2021	pypd	Exercise Of Warrants ExerciseOfWarrants	632000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	402000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42601000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35960000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	4307000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4423000	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	588000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	108000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-39557000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5829000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-39557000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42601000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-36869000	usd
CY2022	us-gaap	Depreciation Depreciation	1721000	usd
CY2021	us-gaap	Depreciation Depreciation	1118000	usd
CY2020	us-gaap	Depreciation Depreciation	1012000	usd
CY2020	pypd	Reevaluation Of Warrants ReevaluationOfWarrants	11373000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-289000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4307000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4750000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	4577000	usd
CY2022	pypd	Decreaseincrease In Receivables And Prepaid Expenses DecreaseincreaseInReceivablesAndPrepaidExpenses	-1185000	usd
CY2021	pypd	Decreaseincrease In Receivables And Prepaid Expenses DecreaseincreaseInReceivablesAndPrepaidExpenses	-83000	usd
CY2020	pypd	Decreaseincrease In Receivables And Prepaid Expenses DecreaseincreaseInReceivablesAndPrepaidExpenses	1929000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-299000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3095000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2221000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-607000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2548000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1416000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2043000	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	847000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34317000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32386000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21596000	usd
CY2022	pypd	Payments For Proceeds From Shortterm And Longterm Deposits Net PaymentsForProceedsFromShorttermAndLongtermDepositsNet	-18342000	usd
CY2021	pypd	Payments For Proceeds From Shortterm And Longterm Deposits Net PaymentsForProceedsFromShorttermAndLongtermDepositsNet	-39893000	usd
CY2020	pypd	Payments For Proceeds From Shortterm And Longterm Deposits Net PaymentsForProceedsFromShorttermAndLongtermDepositsNet	39592000	usd
CY2021	pypd	Prepayment For Equipments PrepaymentForEquipments	340000	usd
CY2020	pypd	Prepayment For Equipments PrepaymentForEquipments	395000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1767000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2653000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	781000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16575000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36900000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-40768000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	632000	usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	108000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	402000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	usd
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	62757000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4423000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11711000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	402000	usd
CY2022	pypd	Issuance Of Warrants IssuanceOfWarrants	-588000	usd
CY2020	pypd	Issuance Of Warrants IssuanceOfWarrants	-1000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16428000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1034000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	62774000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1314000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5548000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	410000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10456000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4908000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4498000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9142000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10456000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4908000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	734000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8552000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9819000	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4319000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	511000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	397000	usd
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	390000	usd
CY2022	pypd	Restricted Cash Included In Other Longterm Assets RestrictedCashIncludedInOtherLongtermAssets	79000	usd
CY2021	pypd	Restricted Cash Included In Other Longterm Assets RestrictedCashIncludedInOtherLongtermAssets	240000	usd
CY2020	pypd	Restricted Cash Included In Other Longterm Assets RestrictedCashIncludedInOtherLongtermAssets	199000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9142000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10456000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4908000	usd
CY2022	pypd	Purchase Of Property And Equipment Included In Trade Payable PurchaseOfPropertyAndEquipmentIncludedInTradePayable	100000	usd
CY2021	pypd	Purchase Of Property And Equipment Included In Trade Payable PurchaseOfPropertyAndEquipmentIncludedInTradePayable	941000	usd
CY2022	pypd	Property And Equipment Paid For In Prior Periods PropertyAndEquipmentPaidForInPriorPeriods	340000	usd
CY2021	pypd	Property And Equipment Paid For In Prior Periods PropertyAndEquipmentPaidForInPriorPeriods	395000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3528000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1259000	usd
CY2022	us-gaap	Basis Of Accounting BasisOfAccounting	<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in; text-align: left">NOTE 1:-</td><td style="text-align: justify">GENERAL</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">PolyPid Ltd. (the “Company”) was incorporated under the laws of Israel and commenced operations on February 28, 2008. The Company is a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company’s product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of its lead product candidate, D-PLEX, which incorporates an antibiotic for the prevention of surgical site infection in bone and soft tissue. Through December 31, 2022, the Company has been primarily engaged in research and development.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">The Company’s wholly owned subsidiaries include a subsidiary in the United States of America (the “US Subsidiary”) and a subsidiary in Romania. The US Subsidiary’s operation focuses on marketing and business development of the Company’s operation in the United States of America.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">On June 21, 2020, the Company’s Board of Directors resolved to consolidate the Company’s share capital by applying a reverse share split at a ratio of 1.046:1 (the “Reverse Split Ratio”) and to cancel the shares’ par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the “Split”). The Split was applied in the same proportion and manner to all of the Company’s authorized, issued and outstanding securities, including preferred shares, options and warrants (See Note 10.a).</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">On June 30, 2020, the Company closed its initial public offering (“IPO”) whereby 4,312,500 Ordinary shares were sold by the Company to the public (inclusive of 562,500 Ordinary shares pursuant to the full exercise of an overallotment option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were $62,757, net of underwriting discounts and other offering costs.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.5in">d.</td><td style="text-align: justify">The Company’s activities since inception have consisted of performing research and development activities. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company’s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">In September 2022, the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX<sub>100</sub> (“SHIELD”) I Phase 3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (“SSIs”), re-interventions due to SSIs and mortality: in the Intent to Treat (“ITT”) population, the local administration of D-PLEX<sub>100</sub> and standard of care (“SoC”), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">That said, in a pre-specified subgroup ITT analysis requested by the United States (“U.S.”) Food and Drug Administration of a total of 423 subjects with large incisions (>20 centimeters), the local administration of D-PLEX<sub>100 </sub>resulted in a significant reduction of 54 percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX<sub>100</sub> treatment arm (n=212).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business plan, the Company will need to complete phase 3 clinical studies and certain development activities as well as manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company’s product candidates will require regulatory approval prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31, 2022, the Company had cash, cash equivalents and short-term deposits in the total amount of $12,594. During the year ended December 31, 2022, the Company incurred a net loss of $39,557 and had negative cash flows from operating activities of $34,317. In addition, the Company had an accumulated deficit of $214,444 at December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company’s future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company’s product candidates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">There can be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Based on the abovementioned, as of the approval date of these consolidated financial statements, the Company has not raised the necessary funding in order to continue its activity for a period of at least one year after the date of the filing of this annual report on Form 20-F. Therefore, these factors raise a substantial doubt about the Company’s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Company be unable to continue as a going concern.</p>
CY2020Q2	pypd	Description Of Reverse Share Split DescriptionOfReverseShareSplit	the Company’s Board of Directors resolved to consolidate the Company’s share capital by applying a reverse share split at a ratio of 1.046:1 (the “Reverse Split Ratio”) and to cancel the shares’ par value such that every 1.046 Ordinary shares of NIS 0.8 par value, were substituted by 1 Ordinary share with no par value (the “Split”). The Split was applied in the same proportion and manner to all of the Company’s authorized, issued and outstanding securities, including preferred shares, options and warrants (See Note 10.a).
CY2020Q2	pypd	Aggregate Net Proceeds AggregateNetProceeds	62757000	usd
CY2022Q3	pypd	Description Administration DescriptionAdministration	the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX100 (“SHIELD”) I Phase 3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (“SSIs”), re-interventions due to SSIs and mortality: in the Intent to Treat (“ITT”) population, the local administration of D-PLEX100 and standard of care (“SoC”), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).That said, in a pre-specified subgroup ITT analysis requested by the United States (“U.S.”) Food and Drug Administration of a total of 423 subjects with large incisions (>20 centimeters), the local administration of D-PLEX100 resulted in a significant reduction of 54 percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX100 treatment arm (n=212).
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	12594000	usd
CY2022	pypd	Incurred Loss IncurredLoss	39557000	usd
CY2022	pypd	Cash Flows From Operating Activities CashFlowsFromOperatingActivities	34317000	usd
CY2022Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	214444000	usd
CY2022	us-gaap	Debt Instrument Term DebtInstrumentTerm	P1Y
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p>
CY2022	pypd	Computersand Software ComputersandSoftware	0.33	pure
CY2022	pypd	Property Plant And Equipment Percent PropertyPlantAndEquipmentPercent	0.15	pure
CY2022	us-gaap	Property Plant And Equipment Estimated Useful Lives PropertyPlantAndEquipmentEstimatedUsefulLives	Over the shorter of the term of the lease or its useful life
CY2022Q1	pypd	Righttouse Assets And Lease Liabilities RighttouseAssetsAndLeaseLiabilities	3388000	usd
CY2022Q1	pypd	Lease Prepayments LeasePrepayments	36000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	738000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	542000	usd
CY2022	pypd	Received Total Amount ReceivedTotalAmount	7193000	usd
CY2022Q4	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	4888000	usd
CY2022	pypd	Nonroyalty Bearing Grants Amount NonroyaltyBearingGrantsAmount	1578000	usd
CY2022	pypd	Out Of Received Amount OutOfReceivedAmount	521000	usd
CY2022	pypd	Nonroyalty Bearing Grants NonroyaltyBearingGrants	727000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-12000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	28000	usd
CY2022	pypd	Financial Expense Income FinancialExpenseIncome	273000	usd
CY2021	pypd	Financial Expense Income FinancialExpenseIncome	-58000	usd
CY2020	pypd	Financial Expense Income FinancialExpenseIncome	-81000	usd
CY2022Q4	pypd	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2022	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.5in">s.</td><td style="text-align: justify">Revenue recognition:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company recognizes revenue from contracts with customers under ASC No. 606, “<i>Revenue from Contracts with Customers</i>”. Accordingly, the Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">To determine revenue recognition for contracts with customers, the Company performs the following five steps:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(i) identify the contract(s) with a customer;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(ii) identify the performance obligations in the contract;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iii) determine the transaction price;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(iv) allocate the transaction price to the performance obligations in the contract; and</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">(v) recognize revenue when (or as) the Company satisfies its performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">At contract inception, the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On August 2, 2022, the Company entered into a license, distribution and supply agreement (the “Agreement”) with Mercury Pharma Group Limited, under the trade name Advanz Pharma Holdings (the “Customer”), with respect to the Company’s product, the D-PLEX<sub>100</sub> (the “Product”), for the prevention of (i) post abdominal surgery incisional infection; and/or (ii) post cardiac surgery sternal infection.</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The term of the Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum sales requirements for that territory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Under the terms of the Agreement, the Company received a non-refundable, one-time payment of €2.5 million (approximately $2,548). The Company is also entitled to receive additional development-related milestones payments for a total of up to €23 million. In addition, the Company will be entitled to receive up to additional €87 million upon achievement of certain commercial sale milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company has concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own or with resources readily available to the Customer because of the Company’s specialized knowledge and the associated manufacturing know-how and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated the transaction price at €2.5 million (approximately $2,548).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">As of December 31, 2022, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly, the upfront payment amount was classified as a long-term deferred revenue in the Company’s consolidated balance sheet as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p>
CY2022	pypd	Agreement Term AgreementTerm	P10Y
CY2022	pypd	Non Refundable Amount NonRefundableAmount	2500000	eur
CY2022	pypd	Non Refundable Amount NonRefundableAmount	2548000	usd
CY2022	pypd	Additional Developmentrelated Milestones Payments AdditionalDevelopmentrelatedMilestonesPayments	23000000	eur
CY2022	pypd	Additional Amount Of Commercial Sale Milestones AdditionalAmountOfCommercialSaleMilestones	87000000	eur
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2500000	eur
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2548000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"/><td style="width: 0.5in; text-align: left">t.</td><td style="text-align: justify">Concentration of credit risks:</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel and in the United States of America. Such investments may be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Company utilizes option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion of the Company’s non-dollar currency exposure. Counterparties to the Company’s derivative instruments are all major financial institutions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 0in"> </p>
CY2022Q4	pypd	Monthly Deposits At A Rate monthlyDepositsAtARate	0.0833	pure
CY2022	pypd	Severance Pay Expense Amount SeverancePayExpenseAmount	537000	usd
CY2021	pypd	Severance Pay Expense Amount SeverancePayExpenseAmount	547000	usd
CY2020	pypd	Severance Pay Expense Amount SeverancePayExpenseAmount	394000	usd
CY2022Q4	pypd	Severance Pay SeverancePay	All eligible employees may elect to contribute up to 100% of their payroll compensation (minus mandatory payroll deductions) to the plan, for 2022, up to a maximum of $20,500 per year (for employees over 50 years of age the maximum contribution was $28,000 per year), as determined by the U.S. Internal Revenue Service (“IRS”). The US Subsidiary matches at 100%, on each payroll, up to 5% of the employee compensation to the plan within the IRS limits (which was set at $300 in 2022 for purposes of the plan).
CY2022	pypd	Matching Contributions Amounts MatchingContributionsAmounts	30000	usd
CY2021	pypd	Matching Contributions Amounts MatchingContributionsAmounts	28000	usd
CY2022Q4	us-gaap	Obligation With Joint And Several Liability Arrangement Corresponding Entry Amount ObligationWithJointAndSeveralLiabilityArrangementCorrespondingEntryAmount	3388	usd
CY2022	pypd	Recently Issued Accounting Pronouncements Not Yet Adopted RecentlyIssuedAccountingPronouncementsNotYetAdopted	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"/><td style="width: 0.5in">x.</td><td style="text-align: justify">Recently issued accounting pronouncements, not yet adopted:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, “<i>Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i>,” which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company beginning January 1, 2023, and interim periods thereafter. The Company adopted ASU 2016-13 on January 1, 2023. The adoption of the standard did not result in a material impact to the Company’s consolidated financial statements.</p>
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15222000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13015000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5975000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4254000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9247000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8761000	usd
CY2022	us-gaap	Depreciation Depreciation	1721000	usd
CY2021	us-gaap	Depreciation Depreciation	1118000	usd
CY2020	us-gaap	Depreciation Depreciation	1012000	usd
CY2022	us-gaap	Capital Leases Indemnification Agreements Payments CapitalLeasesIndemnificationAgreementsPayments	213000	usd
CY2022Q4	pypd	Operating Lease Assets OperatingLeaseAssets	2431000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	959000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1173000	usd
CY2022Q4	pypd	Lease Liabilities LeaseLiabilities	2132000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M13D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0995	pure
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1344000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1047000	usd
CY2022	dei	Entity Registrant Name EntityRegistrantName	PolyPid Ltd.
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	439000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	385000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	367000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	186000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	2424000	usd
CY2022Q4	us-gaap	Receivable With Imputed Interest Net Amount ReceivableWithImputedInterestNetAmount	292000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2132000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1259000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3528000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1246000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1787000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1167000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1879000	usd
CY2021Q4	pypd	Israel Innovation Authority Grant Received IsraelInnovationAuthorityGrantReceived	269000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2429000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3940000	usd
CY2022Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	15000000	usd
CY2022Q2	us-gaap	Line Of Credit Facility Maximum Monthend Outstanding Amount LineOfCreditFacilityMaximumMonthendOutstandingAmount	10000000	usd
CY2022Q3	us-gaap	Line Of Credit Facility Maximum Monthend Outstanding Amount LineOfCreditFacilityMaximumMonthendOutstandingAmount	2500000	usd
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.08	pure
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.14
CY2022Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1000000	usd
CY2022Q4	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.0925	pure
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	734000	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	468000	usd
CY2022	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants.
CY2022	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	1023000	usd
CY2022	pypd	Proceeds From Participation Payments ProceedsFromParticipationPayments	4888000	usd
CY2022	pypd	Commitments And Contingent Liabilities Description CommitmentsAndContingentLiabilitiesDescription	the Company is committed to pay royalties at a rate of 3% of sales of the developed products, up to 100% of the amount of grants received plus interest at LIBOR rate. Through December 31, 2022, no royalties have been paid or accrued.
CY2016Q4	pypd	Finders Fee FindersFee	250000	usd
CY2017Q3	pypd	Suit Filling Expense SuitFillingExpense	250000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	39557000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	42601000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	36869000	usd
CY2022Q4	us-gaap	Tax Basis Of Investments Cost For Income Tax Purposes TaxBasisOfInvestmentsCostForIncomeTaxPurposes	152107000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34984000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31289000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5376000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5203000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	490000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	157000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	239000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	479000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	41007000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	37210000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40448000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	37210000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	559000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	559000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	559000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.003	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	129000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	129000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	129000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	129000	usd
CY2022Q4	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	47800000	shares
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	19851833	shares
CY2022Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	19851833	shares
CY2021Q4	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	47800000	shares
CY2021Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	18756570	shares
CY2021Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	18756570	shares
CY2021Q3	pypd	Aggregate Offering Price AggregateOfferingPrice	45000000	usd
CY2022	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	1065057	shares
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	4423000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	222000	usd
CY2022Q2	pypd	Share Option Plan Description ShareOptionPlanDescription	On May 3, 2022, the annual and extraordinary general meeting of shareholders of the Company approved a new grant of 76,120 options to the then current Chief Executive Officer of the Company, Mr. Amir Weisberg. In addition, it was approved to accelerate the vesting of 12,906 options from an outstanding grant; in both cases the vesting of all options will occur on June 30, 2022. As a result, the Company recognized a total share-based compensation expense in the amount of $76.
CY2022Q2	pypd	Number Of Options NumberOfOptions	1000000	shares
CY2022	pypd	Weighted Average Grant Date Fair Value Of Options Granted WeightedAverageGrantDateFairValueOfOptionsGranted	3.46
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	pypd	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4307000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4750000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4577000	usd
CY2022	pypd	Unrecognized Compensation Costs UnrecognizedCompensationCosts	6379000	usd
CY2022	pypd	Recognized Over Weighted Average Period RecognizedOverWeightedAveragePeriod	P2Y6M
CY2022Q2	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	468000	usd
CY2022Q3	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	120000	usd
CY2022	pypd	Warrants Description WarrantsDescription	During the year ended December 31, 2021, 580,028 D-2 warrants were exercised into 115,982 Ordinary shares on a cashless basis. In addition, 68,491 D-2 warrants were exercised into 68,491 Ordinary shares for a total consideration of $632. As of December 31, 2022, no D-2 warrants are outstanding.
CY2022	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	1023000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	316000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	26000	usd
CY2020	us-gaap	Other Expenses OtherExpenses	17000	usd
CY2020	pypd	Remeasurement Of Warrants RemeasurementOfWarrants	11373000	usd
CY2022	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	1339000	usd
CY2021	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	26000	usd
CY2020	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	11390000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	532000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	44000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	243000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	267000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	468000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	474000	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	58000	usd
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	76000	usd
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	799000	usd
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	570000	usd
CY2020	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	793000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	540000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	-544000	usd
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	10597000	usd
CY2022Q4	pypd	Service Providers In Amount ServiceProvidersInAmount	174000	usd
CY2021Q4	pypd	Service Providers In Amount ServiceProvidersInAmount	199000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1422000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3748000	usd
CY2023Q1	pypd	Exercise Price Decrease ExercisePriceDecrease	2021599	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.77
CY2023Q4	pypd	Minimum Paid Amount MinimumPaidAmount	1500	usd
CY2023Q4	pypd	Exceed Amount ExceedAmount	3000	usd
CY2023Q1	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	10357139	shares
CY2023Q1	pypd	Offering Expenses Payable OfferingExpensesPayable	7081	usd
CY2022	us-gaap	Undistributed Continuing Operation Earnings Loss Allocation To Participating Securities Basic UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic	39557000	usd
CY2021	us-gaap	Undistributed Continuing Operation Earnings Loss Allocation To Participating Securities Basic UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic	42601000	usd
CY2020	us-gaap	Undistributed Continuing Operation Earnings Loss Allocation To Participating Securities Basic UndistributedContinuingOperationEarningsLossAllocationToParticipatingSecuritiesBasic	36869000	usd
CY2020	pypd	Preferred Share Preference PreferredSharePreference	3933000	usd
CY2020	pypd	Deemed Dividend DeemedDividend	2114000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	39557000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	42601000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	42916000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19426692	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18721528	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9582405	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.28
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.48
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2487447	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1995749	shares
CY2020	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1583210	shares
CY2022	pypd	Weighted Average Effect Of Dilutive Securities Warrants To Convertible Preferred Sharesin Shares WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares	413263	shares
CY2021	pypd	Weighted Average Effect Of Dilutive Securities Warrants To Convertible Preferred Sharesin Shares WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares	218521	shares
CY2020	pypd	Weighted Average Effect Of Dilutive Securities Warrants To Convertible Preferred Sharesin Shares WeightedAverageEffectOfDilutiveSecuritiesWarrantsToConvertiblePreferredSharesinShares	867040	shares
CY2022	pypd	Weighted Average Number Of Shares Issued WeightedAverageNumberOfSharesIssued	2900710	shares
CY2021	pypd	Weighted Average Number Of Shares Issued WeightedAverageNumberOfSharesIssued	2214270	shares
CY2020	pypd	Weighted Average Number Of Shares Issued WeightedAverageNumberOfSharesIssued	2450250	shares
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	pypd	Deemed Dividends DeemedDividends		usd
CY2021	pypd	Deemed Dividends DeemedDividends		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.28
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.48
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18721528	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19426692	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9582405	shares
CY2020	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings		usd
CY2022	pypd	Reevaluation Of Warrants ReevaluationOfWarrants		usd
CY2021	pypd	Reevaluation Of Warrants ReevaluationOfWarrants		usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2022	pypd	Prepayment For Equipments PrepaymentForEquipments		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2021	pypd	Issuance Of Warrants IssuanceOfWarrants		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2020	pypd	Purchase Of Property And Equipment Included In Trade Payable PurchaseOfPropertyAndEquipmentIncludedInTradePayable		usd
CY2020	pypd	Property And Equipment Paid For In Prior Periods PropertyAndEquipmentPaidForInPriorPeriods		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2020	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q4	pypd	Israel Innovation Authority Grant Received IsraelInnovationAuthorityGrantReceived		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	pypd	Domestic Israel DomesticIsrael		usd
CY2021	pypd	Domestic Israel DomesticIsrael		usd
CY2020	pypd	Domestic Israel DomesticIsrael		usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	pypd	Warrants Outstanding WarrantsOutstanding		shares
CY2021	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
CY2020	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
CY2022	pypd	Remeasurement Of Warrants RemeasurementOfWarrants		usd
CY2021	pypd	Remeasurement Of Warrants RemeasurementOfWarrants		usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet		usd
CY2022	pypd	Preferred Share Preference PreferredSharePreference		usd
CY2021	pypd	Preferred Share Preference PreferredSharePreference		usd
CY2022	pypd	Deemed Dividend DeemedDividend		usd
CY2021	pypd	Deemed Dividend DeemedDividend		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.28
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.48
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001611842

Files In Submission

Name	View Source	Status
0001213900-23-025399-index-headers.html	Edgar Link	pending
0001213900-23-025399-index.html	Edgar Link	pending
0001213900-23-025399.txt	Edgar Link	pending
0001213900-23-025399-xbrl.zip	Edgar Link	pending
f20f2022ex12-1_polypidltd.htm	Edgar Link	pending
f20f2022ex12-2_polypidltd.htm	Edgar Link	pending
f20f2022ex13-1_polypidltd.htm	Edgar Link	pending
f20f2022ex13-2_polypidltd.htm	Edgar Link	pending
f20f2022ex15-1_polypidltd.htm	Edgar Link	pending
f20f2022ex2-2_polypidltd.htm	Edgar Link	pending
f20f2022_polypidltd.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pypd-20221231.xsd	Edgar Link	pending
pypd-20221231_def.xml	Edgar Link	unprocessable
pypd-20221231_lab.xml	Edgar Link	unprocessable
pypd-20221231_pre.xml	Edgar Link	unprocessable
f20f2022_polypidltd_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pypd-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PYPD
PolyPid Ltd Stock $pypd

2022 Q4 Form 20-F Financial Statement

#000121390023025399 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PYPD PolyPid Ltd Stock $pypd

2022 Q4 Form 20-F Financial Statement

#000121390023025399 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PYPD
PolyPid Ltd Stock $pypd